{
    "clinical_study": {
        "@rank": "132732", 
        "arm_group": [
            {
                "arm_group_label": "Intravenous methylene blue administration", 
                "arm_group_type": "Experimental", 
                "description": "2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion for 6hrs"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Normal saline administration instead of methylene blue"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to see whether the intravenous administration of methylene blue improves the\n      outcome in severe sepsis and septic shock."
        }, 
        "brief_title": "Methylene Blue in Severe Sepsis and Septic Shock", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Severe Sepsis", 
            "Septic Shock"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Sepsis", 
                "Toxemia", 
                "Shock", 
                "Shock, Septic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The mortality of septic shock is still high ranging from 30 to 50%. Vasopressor is the main\n      part in managing septic shock, but the choice of vasopressor is still under-investigated,\n      and area of uncertainty.\n\n      The response to vasopressor is sometimes unsatisfactory, and in that case, the outcome of\n      the patients is poor.\n\n      Recently, small size clinical trial has investigated the effect of methylene blue (MB), and\n      showed promising results. However, large sized phase III trial has not been performed yet.\n\n      Large sized phase III clinical trial is needed to establish the effect of MB in septic\n      shock."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Septic shock meeting the criteria of 2012 surviving sepsis campaign\n\n          -  Need the norepinephrine of over 0.2microgram/kg/min\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Less than 18 years old\n\n          -  Immunosuppressant patients (e.g. on steroid medication, active anti-cancer\n             chemotherapeutic agent, etc.)\n\n          -  Declined consents\n\n          -  glucose-6-phosphate dehydrogenase deficiency\n\n          -  Medication of Serotonin modulator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "354", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797978", 
            "org_study_id": "B-1210/173-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intravenous methylene blue administration", 
                "description": "Initial history taking and physical examination --> enrollment --> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs", 
                "intervention_name": "Intravenous methylene blue administration", 
                "intervention_type": "Drug", 
                "other_name": [
                    "methylene blue administration", 
                    "MB administration"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methylene Blue"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sepsis", 
            "Septic shock", 
            "Methylene blue"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "dremkks@snubh.org", 
                    "last_name": "Kyuseok Kim, MD", 
                    "phone": "+82-31-787-7572"
                }, 
                "facility": {
                    "address": {
                        "city": "Seongnam-si", 
                        "country": "Korea, Republic of", 
                        "state": "Kyeongi-do"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dremkks@snubh.org", 
                    "last_name": "Kyuseok Kim", 
                    "phone": "+82-31-787-7572"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dremkks@snubh.org", 
                    "last_name": "Kyuseok Kim", 
                    "phone": "+82-31-787-7572"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "SMG - SNU Boramae Medical Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Infusion of Methylene Blue in Severe Sepsis and Septic Shock: Randomized, Single Blinded", 
        "overall_contact": {
            "email": "dremkks@snubh.org", 
            "last_name": "Kyuseok Kim, MD", 
            "phone": "+82-31-787-7572"
        }, 
        "overall_contact_backup": {
            "email": "mickeyp@snubh.org", 
            "last_name": "Chanjong Park, MD", 
            "phone": "+82-10-3902-3291"
        }, 
        "overall_official": {
            "affiliation": "Professor, department of emergency medicine", 
            "last_name": "Kyuseok Kim, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "28 day mortality", 
            "safety_issue": "No", 
            "time_frame": "within 28 days of diagnosis"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797978"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Vasopressor dependent period", 
                "safety_issue": "No", 
                "time_frame": "within 28 days of diagnosis"
            }, 
            {
                "measure": "Vasopressor index", 
                "safety_issue": "No", 
                "time_frame": "with in 28 days of diagnosis"
            }, 
            {
                "description": "EV1000 (Edwards inc.) will be used to see the cardiac output and systemic vascular resistance.", 
                "measure": "Change of cardiac output (CO) and systemic vascular resistance (SVR)", 
                "safety_issue": "No", 
                "time_frame": "with in 28 days of diagnosis"
            }, 
            {
                "measure": "Length of stay in ICU (LOSICU)", 
                "safety_issue": "No", 
                "time_frame": "with in 28 days of diagnosis"
            }, 
            {
                "measure": "LOS in hospital", 
                "safety_issue": "No", 
                "time_frame": "with in 28 days of diagnosis"
            }, 
            {
                "measure": "In hospital mortality", 
                "safety_issue": "No", 
                "time_frame": "with in 28 days of diagnosis"
            }, 
            {
                "measure": "Multiple organ failure (SOFA)", 
                "safety_issue": "No", 
                "time_frame": "with in 28 days of diagnosis"
            }, 
            {
                "measure": "NO level", 
                "safety_issue": "No", 
                "time_frame": "before and after infusion of MB, 24hrs, 48hrs later"
            }, 
            {
                "measure": "Cytokine level (IL-6, 10, tumor necrosis factor -alpha)", 
                "safety_issue": "No", 
                "time_frame": "before and after infusion of MB, 24hrs, 48hrs later"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}